1. |
Contraception: developments reviewed |
|
Inpharma Weekly,
Volume &NA;,
Issue 1267,
2000,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
2. |
News in brief... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1267,
2000,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
3. |
Use of USPHS PEP guidelines supported by modelling study |
|
Inpharma Weekly,
Volume &NA;,
Issue 1267,
2000,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
4. |
Epidermal growth factor promising in duodenal ulcers |
|
Inpharma Weekly,
Volume &NA;,
Issue 1267,
2000,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
5. |
Lycopene protects against exercise-induced asthma |
|
Inpharma Weekly,
Volume &NA;,
Issue 1267,
2000,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
6. |
The advancement of anakinra in RA |
|
Inpharma Weekly,
Volume &NA;,
Issue 1267,
2000,
Page 7-8
Ngaire Polwart,
Preview
|
|
摘要:
Anakinra, Amgen's new therapy for rheumatoid arthritis (RA), appears to have potential in slowing joint damage progression and improving quality of life (QOL), according to new data presented at the 64th Annual Scientific Meeting of the American College of Rheumatology [Philadelphia, US; October-November 2000]. Anakinra is currently awaiting approval for the treatment of RA in the US, Europe, Canada and Australia.
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
7. |
News in brief... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1267,
2000,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
8. |
ID hepatitis B vaccination feasible in haemodialysis patients |
|
Inpharma Weekly,
Volume &NA;,
Issue 1267,
2000,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
9. |
News in brief... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1267,
2000,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
10. |
Statins - early administration best in ACS |
|
Inpharma Weekly,
Volume &NA;,
Issue 1267,
2000,
Page 11-12
Carmen Innes,
Preview
|
|
摘要:
Early aggressive lipid-lowering therapy with atorvastatin significantly reduces recurrent ischaemic events in patients who have experienced an acute coronary syndrome (ACS), according to results from the MIRACL*study, which was presented at the 73rd Scientific Sessions of the American Heart Association (AHA) [New Orleans, US; November 2000]. While the MIRACL results look set to change the treatment strategy for such patients, results from the FLORIDA*trial show no benefit of early fluvastatin treatment in reducing post-myocardial infarction (MI) ischaemia.
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|